Mvabea
Ebola vaccine (MVA-BN-Filo [recombinant])
Table of contents
Overview
Mvabea is a vaccine to protect adults and children aged one year and older against Ebola virus disease caused by Zaire ebolavirus. It is used with another Ebola vaccine called Zabdeno as part of a vaccine regimen.
Mvabea contains a virus known as Vaccinia Ankara Bavarian Nordic which has been modified to produce 4 proteins from Zaire ebolavirus and three other viruses of the same group (filoviridae). The modified vaccinia Ankara Bavarian Nordic virus itself has no effect on humans. Mvabea only contains parts of the viruses and cannot cause Ebola virus disease.
-
List item
Mvabea : EPAR - Medicine overview (PDF/137.22 KB)
First published: 23/07/2020
EMA/298993/2020 -
-
List item
Mvabea : EPAR - Risk-management-plan summary (PDF/143.26 KB)
First published: 23/07/2020
Authorisation details
Product details | |
---|---|
Name |
Mvabea
|
Agency product number |
EMEA/H/C/005343
|
Active substance |
Recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP
|
International non-proprietary name (INN) or common name |
Ebola vaccine (MVA-BN-Filo [recombinant])
|
Therapeutic area (MeSH) |
Hemorrhagic Fever, Ebola
|
Anatomical therapeutic chemical (ATC) code |
J07BX
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Exceptional circumstances |
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance. |
Publication details | |
---|---|
Marketing-authorisation holder |
Janssen-Cilag International N.V.
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
01/07/2020
|
Contact address |
Turnhoutseweg 30 |
Product information
20/07/2023 Mvabea - EMEA/H/C/005343 - II/0018/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
Active immunization for prevention of disease caused by Ebola virus (Zaire Ebolavirus species) in individuals ≥ 1 year of age.